BG-75202 features among several projects starting first-in-human trials.
ApexOnco Front Page
Recent articles
There will soon be three PD-(L)1 x VEGF projects in pivotal lung and colorectal cancer trials.
An anti-integrin β6 ADC and a CDK4 inhibitor shoot for bigger markets.
But the timeline for a US green light is less clear, and the group has a cash crisis.
First-in-human trial initiations include Biocytogen's DM002 and Day One's DAY301.
The private group taps DualityBio for an EGFR x HER3 ADC.
Galapagos distances itself from Gilead, and offers a pure-play oncology cell therapy focus.
Clinical expansion shows regulators getting comfortable with in vivo-generated cell therapy.
